App-Quantinova.ai

Pin1 is a novel target of withaferin A, a mammary cancer chemopreventative steroidal lactone from Withania somnifera

Suman K. Samanta - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Effect of equol on hormone-dependent rat mammary carcinoma induced by ethyl methanesulphonate (EMS)

MISAKI ONO - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Alora

The NALP3 inflammasome and IL-1a signaling link asbestos-induced inflammation with the development of malignant mesothelioma

Yuwaraj Kadariya - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Anakinra

Molecular characterization of breast tumor T-cell infiltration in exome datasets

Olivier Harismendy - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Improved geometric deconvolution of bulk tumor genomic data

Theodore Roman - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Solid malignancies

N/A

Analysis of cancer-initiating mosaic mutation in germline samples of pediatric cancer patients by next generation sequencing

Xiaotu Ma - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

TP53

Modeling the emergence of resistance to chemotherapeutics with virtual tumor

Frances A. Brightman - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Methadone hydrochloride

Mutation load measured using a 315 gene panel predicts genome-wide mutation load

Artur Veloso - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

p53 isoform A133p53a triple negative breast cancer and increased relapse with neoadjuvant taxanes

Jean-Christophe Bourdon - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Cyclophosphamide

WNT4 mediates endocrine response and resistance in invasive lobular carcinoma cell lines and patient tumor explants

Matthew J. Sikora - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

ABT-165 is a first-in-class therapeutic Dual Variable Domain Immunoglobulin (DVD-IgTM) that targets DLL4 and VEGF for the treatment of cancer

Yingchun Li - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Bevacizumab

Creating a superior, site-specific anti-HER2 antibody-drug conjugate (NG-HER2 ADC) for treatment of solid tumors

Dangshe Ma - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Trastuzumab emtansine

Derivation and characterization of antibodies from immune checkpoint blockade treated cancer patients

Mark Branum - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Ipilimumab

Nanoliposomal targeting of ephrin receptor A2 (EphA2): Preclinical in vitro and in vivo rationale

Walid S. Kamoun - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Docetaxel

A novel MET-EGFR bispecific antibody LY3164530 shows advantage over combining MET and EGFR antibodies in tumor inhibition and overcome resistance

Ling Liu - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

LY3164530

Circadian/melatonin disruption by dim light at night drives paclitaxel resistance in breast cancer via activation of stat3

Steven M. Hill - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Doxorubicin

Acquisition of chemoresistance in tumor cells requires crosstalk between dying and remnant live tumor cells via HMGB1

Junmin Zhou - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Obstetrics/Gynecology

Solid malignancies

Carboplatin

Mapping the metastatic colorectal cancer phospho-proteome for predicting response to cetuximab

Robin Beekhof - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Erbitux

Dissecting chromatin dynamics in malignant progression

Hanseul Yang - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Inactivation of the DLC1 RhoGAP tumor suppressor by point mutation occurs commonly in human cancer and can result from Rho-dependent or Rho-independent mechanisms

Xiaolan Qian - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Solid malignancies

N/A

Filters

41730 Abstracts